Hospital pharma has almost nothing in common with the pharmacy market outside the hospital walls. There is no automatic reimbursement, no national list you join. A drug commission decides what is stocked, a hospital pharmacy buys it, a clinician prescribes it — and a fixed case budget quietly pushes all three toward the cheapest adequate option.
In the German inpatient world there is no automatic reimbursement: most medicines are paid from the hospital's fixed case revenue (the DRG lump sum), so the hospital is the buyer and it is price-sensitive. Access has three gates — the drug commission (Arzneimittelkommission) decides the hospital formulary (Arzneimittelliste), the hospital pharmacy (Krankenhausapotheke) or an external supplying pharmacy procures and dispenses, and the clinician chooses to prescribe. Prices are negotiated directly and confidentially between manufacturer and hospital or purchasing group, with the AMNOG-negotiated price acting as a ceiling. Expensive innovations that don't fit the lump sum may be paid separately via NUB / additional fees. Approval and even an AMNOG price get you none of this automatically.
Companies that have cracked the retail-pharmacy channel often assume the hospital is a smaller version of it. It is a different economy with different incentives.
Outside the hospital, a rebated or reimbursed product flows to patients through community pharmacies under national rules. Inside the hospital, the money works the other way round: for most inpatient treatment the hospital receives a fixed amount per case — the DRG lump sum — and the medicines used come out of that amount. Every euro of drug cost the hospital can avoid is margin it keeps.
That single fact shapes everything. The hospital is not a passive dispenser; it is a professional buyer with a strong reason to prefer the cheapest option that does the job. Your clinical champion wants your product; the person who pays for it wants a discount or a substitute.
In the retail channel the payer reimburses. In the hospital the payer is the buyer — and the buyer keeps what it saves.
A medicine reaches a German inpatient only if all three of these align. Win two and miss one, and you are not stocked.
Decides the hospital formulary — which products are stocked at all. Weighs clinical value against cost and against what is already listed. If you are not on the list, you are effectively not available.
Procures, stores and dispenses. A hospital without its own pharmacy is served by an external supplying pharmacy under contract. This is the commercial counterparty on price.
Actually chooses to use it, within what is listed. Clinical conviction and evidence live here — but a champion cannot prescribe what the commission has not listed.
Understand the money and the behaviour of all three gatekeepers stops being mysterious.
Most inpatient care is reimbursed to the hospital as a fixed sum per treatment case, set by the diagnosis-related group. The drugs given during that stay are, as a rule, paid from that sum. So a more expensive medicine does not bring the hospital more revenue — it reduces the margin on the case, unless it shortens the stay or avoids a costlier complication.
This is why a hospital drug commission behaves like a procurement function with a clinical conscience: it will list what is clinically necessary, but between therapeutically comparable options it has every reason to prefer the cheaper one, or to negotiate the price of yours down. Your value story therefore has to speak the hospital's language: not only better outcomes, but better outcomes that pay for themselves inside the case budget.
A hospital does not earn more for using your drug. It has to save somewhere for choosing it.
Hospital pricing is a private, negotiated world — closer to industrial B2B than to the transparent retail-pharmacy tariff.
| Element | How it works |
|---|---|
| Direct negotiation | Hospitals negotiate drug prices directly with the manufacturer. Discounts are confidential and not publicly known. |
| Size buys leverage | Larger hospitals and clinic chains obtain deeper discounts than small ones; purchasing groups (Einkaufsgemeinschaften) pool demand to negotiate harder. |
| The AMNOG ceiling | For a new medicine, the reimbursement price negotiated at national level under AMNOG sets the effective maximum reference for these hospital deals. |
| Confidential by design | Because discounts are secret, price benchmarking across hospitals is hard — and a bad first reference deal can follow you. |
The AMNOG process decides the ceiling; the hospital negotiation decides what you actually receive beneath it. The two are linked, which is why hospital strategy should be planned before, not after, the benefit assessment — see AMNOG explained.
New for 2026: a GKV cost-containment package raised mandatory manufacturer rebates and extended the price moratorium, and a pilot lets health insurers run tender-style rebate contracts for certain patent-protected medicines through 2030, so innovative drugs can be put into direct price competition with comparable products. The direction of travel is more price pressure, not less.
Not every drug has to fit inside the DRG. Genuinely expensive or novel therapies can be reimbursed separately — through additional fees (Zusatzentgelte) for established high-cost products, or, for genuinely new methods not yet reflected in the tariff, through the NUB route that lets a hospital negotiate a temporary extra payment. Securing this changes the economics entirely: your drug stops competing for the hospital's margin and gets its own funding line.
For a high-cost innovation this is often the difference between being listed and being used. It is also hospital-by-hospital and time-limited work — the same logic we set out for devices in hospital & tender access, applied to medicines.
Because the three gatekeepers answer to different logics, a single-track campaign fails predictably. A workable approach runs them in parallel.
Evidence, guidelines and reference sites — the conviction that makes a clinician want your product.
Total cost within the case, not list price alone: length-of-stay, complications avoided, downstream savings.
A price, terms and logistics the Krankenhausapotheke or purchasing group can say yes to — mindful of the reference it sets.
Pursue Zusatzentgelt or NUB for high-cost products so your drug is not fighting the margin.
There is no national switch. Access is won institution by institution, and purchasing groups multiply the work you have already done.
We help manufacturers build the hospital access plan that authorization and an AMNOG price do not give you — the formulary case, the pricing strategy against the DRG budget, the NUB / Zusatzentgelt question, and the account-by-account rollout.